Skip to main content
. 2023 Jan 30;8(6):5234–5246. doi: 10.1021/acsomega.2c03881

Figure 1.

Figure 1

(A) Chemical structures of the investigational anticoronaviral agent S-217622 (along with its expected comprehensive extended and broad-spectrum anticoronaviral activities against the diverse nonspecific proteins of coronaviruses) and the reference anti-SARS-CoV-2 drug molnupiravir, respectively. (B) Comparative physicochemical radar (preliminary in silico pharmacokinetics/druglikeness assessment; LIPO: Lipophilicity, INSOLU: Insolubility, INSATU: Insaturation, and FLEX: Flexibility) of S-217622 versus molnupiravir, generated using the SwissADME webserver.